Russian Heart Failure Journal 2010year Carvedilol as a part of complex treatment of chronic heart failure in patients with coronary artery disease and chronic obstructive pulmonary disease


To access this material please log in or register

Register Authorize
2010/

Carvedilol as a part of complex treatment of chronic heart failure in patients with coronary artery disease and chronic obstructive pulmonary disease

Evdokimov V. V., Evdokimov A. G., Kovalenko E. V., Radzevich A. E.

Keywords: coronary artery disease, carvedilol, myocardial remodeling, exercise capacity, lung function, chronic obstructive pulmonary disease, CHF, central hemodynamics

DOI: 10.18087/rhfj.2010.2.1276

Actuality. The combination of COPD and coronary artery disease (CAD) with CHF leads to mutual aggravation and requires special approaches to treatment. Thus, the presence of concomitant COPD limits the use of β-blockers. Aim. To study clinical efficacy and safety of carvedilol in patients with CAD, complicated by CHF II-III FC, in conjunction with COPD. Materials and methods. The study involved 44 patients with CHF II-III FC, CAD, moderate and severe COPD. Patients were randomized into two groups. Group 1 received carvedilol (akridilol), 12.5-25 mg per day, additionally to standart treatment of these diseases. Group 2 did not receive carvedilol. At baseline and in 6 months clinical status, exercise capacity (EC), hemodynamics, cardiac remodeling, lung function (LF), quality of life were evaluated. Results. Carvedilol’s addition to complex therapy of CHF, CAD and COPD increases treatment efficacy, improves patients’ clinical status, quality of life, EC. In this clinical situation carvedilol improves hemodynamic parameters, heart’s structural and functional parameters, without affecting LF.
  1. Чучалин А. Г. Респираторная медицина. – М.: ГЕОТАР-медиа. – 2007, – 814.
  2. Агеев Ф. Т., Скворцов А. А., Мареев В. Ю., Беленков Ю. Н. Сердечная недостаточность на фоне ишемической болезни сердца: некоторые вопросы эмидемиологии, патогенеза и лечения. Русский медицинский журнал. 2000;2 (15-16):622–626.
  3. Авдеев С. Н., Царева Н. А., Чучалин А. Г. Лечение легочной гипертензии при хронической обструктивной болезни легких. Журнал Сердечная недостаточность. 2002;3 (3):144–148.
  4. Авдеев С. Н., Баймаканова Г. Е. Стратегия ведения кардиологического пациента, страдающего ХОБЛ. Кардиопульмонологические взаимоотношения. Сердце. 2007;6 (6):305–309.
  5. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest. 2005;128 (4):2640–2646.
  6. Lawless CE. Can beta-blockers be safely titrated in patients with abnormal pulmonary function tests? Abstracts of the 2O’h Annual Meeting and Scientific Sessions of the international society for heart and lung transplantation. – Osaka. – Japan. – 2000.
  7. Преображенский Д. В., Сидоренко Б. А., Дедова И. С, Тарыкина Е. В. Блокаторы β-адренорецепторов в лечении сердечно-сосудистой заболеваний: место карведилола. Кардиология. 2006;47 (12):79–88.
  8. van der Woude HJ, Zaagsma J, Postma DS et al. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest. 2005;127 (3):818–824.
  9. Мареев В. Ю., Арбомишвили Т. Н. Проблемы и перспективы бета-адреноблокаторов в XXI веке. Сердце. 2007;6 (5):3–10.
Evdokimov V. V., Evdokimov A. G., Kovalenko E. V. et al. Carvedilol as a part of complex treatment of chronic heart failure in patients with coronary artery disease and chronic obstructive pulmonary disease. Russian Heart Failure Journal. 2010;11(2):89-91.

To access this material please log in or register

Register Authorize
Ru En